Document:

EX-4.6

 Exhibit 4.6 

DIRECTOR AGREEMENT 
 Eric Strutz 

31 August 2020 
 Dear Eric 

This agreement sets out the terms under which Global Blue Group Holding AG, a company incorporated in Switzerland with registered number CHE-442.546.212 with
its registered office in Wangen-Brüttisellen, Switzerland (the “Company”) appoints you to act as a non-executive director on the board of directors
of the Company (the “Board”) (the “Appointment”). 
  

	1.	 APPOINTMENT 

  

	1.1	 The Appointment shall commence upon the Merger Effective Time (as defined in the Agreement and Plan of Merger
between, inter alia, the Company, S.L. Globetrotter L.P., Far Point Acquisition Corporation and certain members of management dated 16 January 2020) (the “Effective Date”). The Appointment shall continue, subject always
to the provisions of Clauses 1.2, 1.4 and 6.1 below, until terminated in accordance with this agreement and/or Swiss law. On the date of this agreement, you shall deliver to the Company a signed acceptance of appointment form in respect of the
Appointment and thereafter such other documentation as may be required to formalise the Appointment as a matter of Swiss law. 

  

	1.2	 This agreement is subject to the articles of association and the business rules of the Company, as adopted
and/or amended from time to time (the “Articles and Business Rules”), the Swiss Code of Obligations (the “Code”), the Swiss Ordinance against Excessive Compensation in Listed Companies and other laws and regulations
that apply to the Company from time to time. Nothing in this agreement shall be taken to exclude or vary the terms of the Articles and Business Rules as they apply to you as a director of the Company. In the event of a conflict between the terms of
this agreement and the terms of the Articles and Business Rules, the terms of the Articles and Business Rules shall apply. 

  

	1.3	 You shall comply with the rules, regulations and/or requirements of any regulatory body which regulates the
business carried out by the Company or any of its direct or indirect subsidiaries from time to time (the “Group”), including listing authorities and other regulatory authorities with whose rules, regulations and/or requirements the
Group must comply. By accepting this Appointment, you confirm that you are not subject to any restrictions which prevent you from holding office as a director of the Company. In addition, you agree to comply with any insider trading policy and/or
code of conduct of the Company as is in place from time to time. 

  

	1.4	 The Appointment shall be subject to and conditional upon your election and subsequent annual re-election by the shareholders of the Company at an annual general meeting in accordance with Swiss law. 

  

	2.	 DUTIES 

  

	2.1	 By accepting this Appointment, you confirm you are able to allocate sufficient time to discharge your
responsibilities and duties as contemplated by Swiss law and this agreement effectively. You warrant that you have declared any conflicts that are apparent at present. If you become aware of any potential conflicts of interest, these should be
disclosed to the Board as soon as you become aware of them. 

	2.2	 In connection with the Appointment, you agree that you shall join, serve and contribute as the chair of the
Finance & Audit Committee of the Company and as a member of any other committee notified in writing to you by the Company. 

  

	2.3	 Your membership of the committees referred to in Clause 2.2 above shall, at all times and in all respects, be
subject to the Articles and Business Rules, the Code and other laws and regulations that apply to the Company from time to time. 

  

	3.	 EQUITY GRANTS 

 

	3.1	 For the purposes of this Clause 3, the following terms shall have the following meanings:

  

	 	(a)	 “Award Certificate” means, in respect of each RSA granted to you pursuant to this Clause 3, a
certificate setting out the terms of such RSA; 

  

	 	(b)	 “Conversion Rate” means the average of the spot exchange rate as at 5:00 pm, New York time, on
the five (5) trading days ending the trading day before the Grant Date, as published by Bloomberg (through its EURUSD CURNCY function), or any other rate as agreed in writing between you and the Company; 

 

	 	(c)	 “Grant Date” means, in respect of each RSA granted to you pursuant to this Clause 3, the date
on which such RSA is granted; 

  

	 	(d)	 “Market Value” means, on each Grant Date, an amount equal to the average mid-market price of the Shares in the period that is twenty (20) trading days prior to such Grant Date; 

  

	 	(e)	 “MIP” means the management incentive plan to be adopted by the Company on or around the
Effective Date; 

  

	 	(f)	 “MIP Document” means the plan document governing the MIP; and 

 

	 	(g)	 “Shares” means the common shares in the Company. 

 

	3.2	 On the Effective Date (and on the date falling every three years thereafter) and provided that at that time you
are still a director of the Company having been re-elected in accordance with Clause 1.4, you shall be granted a restricted stock award (“RSA”) under the MIP with a value of €80,000
(converted to US$ at the Conversion Rate) based on the Market Value of the Shares on the relevant Grant Date (provided that the Market Value for the first RSA granted to you shall be deemed to be US$10 per Share). To the extent that the calculation
of the total number of Shares subject to any RSA (as set out in this paragraph) results in a fraction of a Share, the number of Shares subject to such RSA shall be rounded down to the nearest whole number and the Fees payable to you in the relevant
year pursuant to Clause 4.1 below shall be increased by an amount equal to the Market Value of that fraction of a Share. 

  

	3.3	 The following specific terms shall apply to each RSA granted to you pursuant to Clause 3.1, and shall be
reflected in each Award Certificate: 

  

	 	(a)	 the vesting schedule in Rule 4 of the MIP shall be amended so that one third of such RSA shall vest on each of
the first, second and third anniversaries of the Grant Date; 

  
 2 

	 	(b)	 Rules 9.1 and 9.2 of the MIP Document shall be deleted in their entirety and replaced with the following:

 “If an Award Holder ceases to be an Employee due to: 

 

	 	a.	 personal incapacity due to ill-health or disability (other than as a
result of alcohol or drug dependency); 

  

	 	b.	 termination by the Company or its shareholders, other than in circumstances where such termination is due to or
preceded by any form of misconduct (in the sole opinion of the Company or its shareholders); 

  

	 	c.	 the Employer Company ceasing to be a Group Company; or 

 

	 	d.	 death, 

any unvested Tranches or portions of Tranches of the Award shall continue to Vest (in the case of the Award Holder’s death, in the Award
Holder’s personal representatives) per the vesting schedule set out in Rule 4.1 (as amended by this Award Certificate)”; and 
  

	 	(c)	 Rules 16.2(c) and 16.4(a) of the MIP Document shall be deleted in their entirety and shall not apply to you.

  

	3.4	 Save as otherwise set out in this Clause 3, each RSA shall be governed by the MIP Document. Each RSA issued to
you and any Shares issued and/or transferred pursuant to an RSA will be held by you subject to the terms of the Articles and Business Rules and any applicable laws. 

 

	3.5	 The RSA shall form part of your compensation as director of the Company. Notwithstanding anything to the
contrary herein, the value and grant of any RSA shall be subject to and conditional upon prior approval by the general meeting of shareholders of the Company of the aggregate board compensation for the respective term of office.

  

	4.	 CASH COMPENSATION 

 

	4.1	 Subject to approval in accordance with Clause 4.5, you shall be paid a total fee of €80,000 per annum
(less any applicable tax, social security or other deductions payable in respect of the €80,000 fee or any RSA granted in accordance with Clause 3) (the “Fees”) payable by or on behalf of the Company annually in respect of the
Appointment. 

  

	4.2	 If the Appointment terminates for any reason, the amount of Fees paid under Clause 4.1 shall be pro-rated to reflect the length of the Appointment in the relevant year. 

  

	4.3	 Other than as expressly set out in this agreement, you are not entitled to receive any other benefits from the
Company, and, upon the termination of the Appointment, you shall not be entitled to receive any payment or other benefit by way of compensation for loss of office, damages or otherwise, other than as provided for in Clauses 4.1 and 4.4.

  

	4.4	 The Company shall reimburse you for all reasonable, documented, out-of-pocket expenses necessarily and wholly incurred by you in the proper performance of your duties subject to you providing the Company with such receipts and other evidence of expenses as the Company may
reasonably require. 

  
 3 

	4.5	 The level and payment of Fees shall be subject to and conditional upon prior approval by the general meeting of
shareholders of the Company of the aggregate board compensation for the respective term of office. 

  

	5.	 INTELLECTUAL PROPERTY 

 

	5.1	 You hereby assign to the Company all existing and future intellectual property rights (including, without
limitation, patents, copyright and related rights) and inventions arising from your duties to the Company. You agree to execute promptly all documents and do all acts as may, in the opinion of the Company, be necessary to give effect to this Clause
5. 

  

	5.2	 You hereby waive all of your moral rights in respect of any acts of the Company or any acts of third parties
done with the Company’s authority in relation to any intellectual property which is the property of the Company. You irrevocably appoint the Company to be your agent in your name and on your behalf to execute documents, use your name and do all
things which are necessary or desirable for the Company to obtain for itself or its nominee the full benefit of this Clause 5. A certificate in writing, signed by any director or the secretary of the Company, that any instrument or act falls within
the authority conferred by this agreement shall be conclusive evidence that such is the case so far as any third party is concerned. 

  

	5.3	 You shall not be entitled to any remuneration (other than the Fees referred to above) in relation to the
assignment or transfer of rights under this Clause 5. 

  

	6.	 TERMINATION OF APPOINTMENT 

 

	6.1	 This agreement may be terminated by either party at any time with immediate effect and without cause, in
accordance with Article 404 of the Code. 

  

	6.2	 The Appointment and your office as director; 

 

	 	(a)	 shall expire and terminate with immediate effect following any annual general shareholders meeting of the
Company at which your re-election is not approved; 

  

	 	(b)	 may be terminated by you at any time by resigning, in accordance with Article 404 of the Code;

  

	 	(c)	 may be terminated by a resolution of the shareholders of the Company at any time with immediate effect and
without cause, in accordance with Article 705 of the Code; and 

  

	 	(d)	 may be suspended by the Company at any time with immediate effect and without cause, provided that the Company
immediately calls for an extraordinary meeting of the shareholders, in accordance with Article 726 of the Code. 

  

	6.3	 Upon termination of this agreement in accordance with Clause 6.1, you agree to resign from your office as a
director of the Company as soon as practicable following such termination. 

  

	6.4	 When the Appointment ceases, or at any time on the request of the Board, you shall immediately return all
documents and other property belonging to the Company or the Group which may be in your possession or under your control, and you undertake to return to the Company all such documents that may come into your possession in the future.

  

	6.5	 Clause 7.1 to 7.3 (inclusive) shall survive termination of this agreement. 

  
 4 

	7.	 NON-COMPETE AND CONFIDENTIALITY 

 

	7.1	 In consideration of the Fees and any RSA received under this agreement, you agree that at any time during the
Appointment, and for a period of one year following the termination of the Appointment for any reason, you shall not, save with the prior written consent of the Board, assume any role for, with or in connection with any business which competes or is
in competition with the Company or the Group, whether as a director, partner, employee, consultant or in any other capacity whatsoever. 

  

	7.2	 You shall not (save in the proper course of your duties, as required by law or as authorised by the Company)
use, disclose or communicate to any person (and shall use your best endeavours to prevent the use, disclosure or communication of) any trade or business secrets or confidential information of or relating to the Company or the Group (including but
not limited to details of actual or potential customers, customer identity, employees, directors, consultants, suppliers, licensors, licensees, agents, distributors, designs, existing and planned product lines, product applications, technology
underlying its products or services, trade arrangements, terms of business, customer requirements, customer lists, operating systems, sales and revenue information, marketing information or strategies, manufacturing processes, software, computer
systems, source codes, disputes, commission or bonus arrangements, pricing and fee arrangements and structures, price lists, business plans, financial information, business transactions, prospective business transactions, inventions, research and
development activities, personal or sensitive personal data and anything marked or otherwise treated as confidential) which you create, develop, receive or obtain in connection with the Appointment and shall not use to the detriment of the Company
or the Group any information relating to the Company or the Group. The restrictions in this Clause 7.2 shall continue to apply after the termination of the Appointment howsoever arising without limit in time. In addition, you shall continue to be
subject to any applicable insider trading or market abuse legislation. 

  

	7.3	 Reference to confidential information in this Clause 7 shall not include information which is in the public
domain at the time of its disclosure or which comes into the public domain after its disclosure otherwise than by reason of a breach of this agreement (and in such a case shall become non-confidential from the
time that the information comes into the public domain), information which was already demonstrably known to the receiving party at the date of disclosure and had not been received in confidence from the Company or information which is required to
be disclosed as a matter of law provided that, to the extent not prohibited by law, you shall notify and consult with the Company prior to making such disclosure. It shall include information in the public domain for so long as you are in a position
to use such information more readily than others who have not worked for the Company. 

  

	8.	 INDEMNIFICATION AND INSURANCE 

 

	8.1	 The indemnification policy adopted by the Board (the “Indemnification Policy”) shall apply to
you from the Effective Date, with respect to the Appointment. You shall also be entitled to be covered by the Company’s D&O insurance policy if, and to the extent that, it has elected to have one in place from time to time.

  

	9.	 MISCELLANEOUS 

 

	9.1	 This agreement (together with any other agreements referred to in it) contains the entire understanding between
the parties and supersedes all (if any) other subsisting agreements, arrangements and understandings (written or oral) relating to your Appointment as a non-executive director of the Company and all such other
agreements, arrangements and understandings shall be deemed to have been entirely replaced by this agreement by mutual consent. You warrant that you have not entered into this agreement in reliance on any warranty, representation or undertaking of
any nature whatsoever which is not expressly contained in or specifically incorporated in this agreement. Any amendments to this agreement shall only be valid if set out in writing and signed by the parties. 

  
 5 

	9.2	 This agreement and all matters (including, without limitation, any contractual or non-contractual obligations) arising from or connected with it are governed by, and will be construed in accordance with, Swiss law and the Swiss courts at the domicile of the Company shall have non-exclusive jurisdiction to settle all disputes arising in connection with any such matters. 

  
 6 

 This agreement has been executed on the date first above written. 

SIGNED by 
  

			
	/s/ Marcel
Erni                                         
               	  	Dated: 31 August 2020
	for and on behalf of	  	

 GLOBAL BLUE GROUP HOLDING AG 

  
 7 

			
	SIGNED by	  	
		
	/s/ Eric Strutz
                                         
           	  	Dated: 27 August 2020
		
	ERIC STRUTZ	  	

  
 8EX-4.7

 Exhibit 4.7 

CONVERSION AGREEMENT 

This CONVERSION AGREEMENT (this “Agreement”) is dated as of 28 August 2020 by and between (i) Global Blue Group
Holding AG, a Swiss corporation (the “Company”), (ii) Global Blue Holding LP, an exempted limited partnership formed under the laws of the Cayman Islands, having its registered office at the offices of Maples Corporate Services
Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and registered in the Cayman Islands General Registry under number 95120 (the “PG Shareholder”), (iii) SL Globetrotter
L.P., an exempted limited partnership formed under the laws of the Cayman Islands, having its registered office at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman,
KY1-1104, Cayman Islands and registered in the Cayman Islands General Registry under number 95120 (the “SL Shareholder” and, together with the PG Shareholder, the “SL/PG
Shareholders”) and (iv) the several persons whose names and addresses are set out in each of his/her respective joinder agreements in a form substantively the same as that set out in Schedule 1 (each a “Manager” and,
together, the “Managers”, and together with the SL/PG Shareholders, the “Holders”). 
 RECITALS:

 WHEREAS, following the closing of a merger agreement (the “Merger Agreement”) by and among, inter
alia, the Company and the Seller Parties (as defined therein), entered into on or around the date hereof, the Company will own the business known as ‘Global Blue’ and the Common Shares (as defined below) of the Company will be listed
on the New York Stock Exchange (the “Exchange”). 
 WHEREAS, in connection with the transactions contemplated by the
Merger Agreement, the Company will issue certain Common Shares and Series A Preferred Shares (as defined below) to certain shareholders of the Company (including the Holders); 

WHEREAS, the Holders may receive a preferred dividend (the “Preferred Dividend”) in accordance with the
articles of association of the Company, as amended from time to time (the “Articles”); and 
 WHEREAS, the Company
and the Holders desire to provide for the issuance and delivery of Common Shares in exchange for Series A Preferred Shares from the Holders in accordance with the terms and conditions herein. 

WHEREAS, it is the Company’s intention that Series A Preferred Shares acquired by the Company from the Holders pursuant to
the terms of this Agreement are subsequently cancelled in accordance with Swiss law. 

 NOW, THEREFORE, in consideration of their mutual promises and agreements, the
parties agree as follows: 
 AGREEMENT 

1. Defined Terms 

1.1 Certain capitalized terms are used in this Agreement with the meanings set forth below in this Clause 1: 

“Affiliate” means with respect to a person (the “First Person”): 

 

	 	(i)	 another person that, directly or indirectly through one or more intermediaries, Controls, or is Controlled by,
or is under common Control with, the First Person; 

  

	 	(ii)	 a pooled investment vehicle organised by the First Person (or an Affiliate thereof) the investments of which
are directed by the First Person (or an Affiliate thereof); 

  

	 	(iii)	 a fund organised by the First Person for the benefit of the First Person’s (or any of its
Affiliates’) partners, officers or employees or their dependants; or 

  

	 	(iv)	 a successor trustee or nominee for, or a successor by reorganisation of, a qualified trust (being a tax
advantaged fiduciary relationship between an employer and an employee in which the employee beneficiary may use his life expectancy to determine required minimum distribution amounts), 

but shall, where applicable, exclude portfolio companies controlled by funds managed directly or indirectly by Silver Lake Technology
Management, L.L.C. or Partners Group or any of their respective Affiliates. 
 “Articles” has the meaning set forth in the
Recitals. 
 “As-Converted Basis” means a calculation of the Series A Preferred
Shares owned by the Holders assuming that all outstanding Series A Preferred Shares that are exchangeable for Common Shares in accordance with the Conversion Ratio pursuant to this Agreement are so exchanged (and, for the avoidance of doubt, without
giving effect to any contractual or other limitation on the exchange of such Series A Preferred Shares that may be in effect from time to time). 

“Business Day” means the days on which commercial banks are generally open for business in both Zurich and in New York. 

“Closing” means the Closing as defined in the Merger Agreement. 

“Closing Date” means the date on which Closing actually occurs. 

“Common Shares” means the registered common shares with a nominal value of CHF 0.01 each of the Company (or any successor of
the Company by combination of shares, recapitalization, merger, consolidation or other reorganization) and any shares into which any such Common Shares shall have been changed or any shares resulting from any reclassification of any such Common
Shares. 

 “Control” means, with respect to a Person (other than an
individual) (a) direct or indirect ownership of more than 50% of the voting securities of such Person, (b) the right to appoint, or cause the appointment of, more than 50% of the members of the board of directors (or similar governing
body) of such Person or (c) the right to manage, or direct the management of, on a discretionary basis, the assets of such Person, and, for the avoidance of doubt, a general partner is deemed to Control a limited partnership and, solely for the
purposes of this Agreement, a fund advised or managed directly or indirectly by a Person shall also be deemed to be Controlled by such Person (and the terms “Controlling” and “Controlled” shall have meanings
correlative to the foregoing). 
 “Conversion Ratio” means the exchange of Series A Preferred Shares for Common Shares on a
one-for-one basis, subject to any adjustments pursuant to Clause 11. 

“Effective Time” means any of the Put Effective Time, Call Effective Time, Redemption Effective Time and the date of a Call
Transfer Notice, as the case may be. 
 “Exchange” has the meaning set forth in the Recitals. 

“Global Blue Group” means the Company, its group companies and its direct and indirect subsidiaries. 

“Governmental Entity” shall mean any national, federal, state, or local, domestic or foreign, governmental, regulatory or
administrative authority, branch, agency or commission or any court, tribunal or judicial body in Switzerland, the United States or elsewhere. 

“Indebtedness” means (a) the unpaid principal and accrued interest with respect to the indebtedness of the Group for
borrowed money (excluding intercompany balances), (b) all obligations of any member of the Group evidenced by bonds, notes, debentures or similar debt instruments and (c) all obligations under leases required to be capitalized in accordance
with IFRS, in each case as determined in a manner consistent with the Company Audited Financial Statements (as defined in the Merger Agreement). 

“Indebtedness Ratio” shall mean an amount equal to (i) Indebtedness divided by (ii) EBITDA (as set forth in the
most recent audited financial statements of the Company from time to time). 
 “Management Representative” means the person
designated as the “Management Representative” in accordance with the Management Shareholders Agreement. 
 “Management
Shareholders Agreement” means the management shareholders agreement dated on or around the date hereof by and among the SL/PG Shareholders, the Managers and the Company. 

“Merger Agreement” has the meaning set forth in the Recitals. 

“Partners Group” means Partners Group Client Access 5, L.P. Inc., Partners Group Private Equity (Master Fund), LLC, and
Partners Group Barrier Reef, L.P.. 

 “Person” means any individual, company, corporation, firm, partnership,
limited liability company, trust or any other business, entity or person, whether or not recognized as constituting a separate legal entity. 

“Preferred Dividend” has the meaning set forth in the Recitals. 

“Preferred Holder Majority” has the meaning set forth in Clause 6.1. 

“Registration Rights Agreement” means the registration rights agreement dated on or around the date hereof by and among the
Company, Global Blue Holding LP, SL Globetrotter, L.P., Far Point LLC, Third Point Offshore Master Fund L.P., Third Point Ultra Master Fund L.P., Third Point Partners Qualified L.P., Third Point Partners L.P. and Third Point Enhanced L.P.. 

“Series A Preferred Shares” means the registered series A convertible preferred shares with a nominal value of CHF 0.01 each
of the Company (or any successor of the Company by combination of shares, recapitalization, merger, consolidation or other reorganization) and any share into which any such Series A Preferred Shares shall have been changed or any shares resulting
from any reclassification of any such Series A Preferred Shares. 
 “Shareholder
Re-Authorization” has the meaning set forth in Clause 4. 
 “Shareholders
Agreement” means the shareholders agreement dated on or around the date hereof by and among SL Globetrotter, L.P., Global Blue Holding LP and Far Point LLC (among other Shareholders as defined therein). 

“Silver Lake” means SL Globetrotter L.P., a limited partnership formed in the Cayman Islands with its registered office at
Ugland House, Grand Cayman, KY1-1104, Cayman Islands. 
 “Trading Day” means any
day on which the Common Shares are actually traded on the principal securities exchange or securities market on which the Common Shares are then traded. 

“Transfer Notice” means any of the Put Transfer Notice, Call Transfer Notice and the Redemption Notice, as the case may be.

 “Value” means the value of a security based on its VWAP for the 30 trading days prior to the Effective Time. 

“VWAP” means, for any security as of any date(s), the daily dollar volume-weighted average price for such security on the
principal securities exchange or securities market on which such security is then traded during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its “HP”
function (with “Market” function set to “VWAP”, “Currency” function set to “USD”, and “Period” function set to “Daily”; the resulting VWAP is shown next to the “Average” label).

 2. Conditionality 

2.1 This Agreement is conditional upon Closing occurring and shall become effective upon Closing and shall thereafter continue
to be effective until terminated in accordance with Clause 16. 
 2.2 If the Merger Agreement is terminated in accordance
with its terms without Closing occurring, this Agreement shall terminate and be of no further effect. 
 3. Maintenance of Treasury
Shares. 
 The Company agrees that from and after the date of this Agreement it will, subject to all applicable laws and regulations,
use reasonable best efforts to take all actions required to maintain and reserve at all times a number of Common Shares in the Company’s treasury (from time to time) (“Treasury Shares”) sufficient from time to time to permit
the issuance and delivery of such number of Common Shares as may be required to satisfy the transactions contemplated herein (including the Conversion Ratio from time to time) except to the extent the Company is able to satisfy its obligations
hereunder through its existing authorized capital. If there are insufficient Treasury Shares to effect any of the transactions contemplated herein (including the Conversion Ratio from time to time), then the Company undertakes, (i) subject to
applicable law (including without limitation the requirements of Art. 659 et seq. of the Swiss Code of Obligations), to acquire Common Shares on the Exchange or (ii) following receipt of a Put Transfer Notice or Call Transfer Notice (as defined
below), to cause a subsidiary to subscribe for a sufficient number of newly issued Common Shares at a price of CHF 0.01 per Common Share, in each case only as and when required to be delivered to the converting Holder. 

4. Maintenance of Authorized Share Capital. 

The Company agrees that from and after the date of this Agreement, to procure that its board of directors will use reasonable best efforts to
take all actions required to maintain and reserve at all times sufficient authorized share capital to permit the issuance and delivery of Common Shares in connection with an exchange for all outstanding Series A Preferred Shares pursuant to any
Transfer Notice, including by proposing to increase the authorized share capital concurrently with any upward adjustment of the number of Common Shares issuable in connection with a Transfer Notice. In furtherance of the foregoing covenant, and to
the extent required taking into account the Treasury Shares, the Company undertakes that its board of directors will timely propose at every second annual general meeting of shareholders (or, if a longer maximum term is permitted by any change in
law, at such annual general meeting before the applicable term expires) to renew and/or increase the authorized share capital provision in its Articles for the statutory maximum term, which is currently two years (any such approval by the
shareholders, a “Shareholder Re-Authorization”), so that the authorized share capital of the Company is sufficient to satisfy the covenant set forth in the first sentence or, if required, to
convene and propose at an extraordinary general meeting of shareholders to renew and/or increase the authorized share capital provision in its Articles, prior to the expiry of its term, so that the authorized share capital of the Company is
sufficient to satisfy the covenant set forth in the first sentence. 

 5. Grant of Put Option 

5.1 Each Holder shall, at least twenty (20) Business Days following and within sixty (60) Business Days following, a
Put Transfer Indication (as defined below), have the right (subject to the terms of the Management Shareholders Agreement) to issue a notice to the Company specifying the date and time on which the Put Option (as defined below) is to be exercised
(the “Put Transfer Notice”), which shall be a date at least five (5) Business Days after the date on which such Put Transfer Notice is delivered to the Company, or such other date and time as such Holder and the Company may
agree (the “Put Effective Time”). 
 5.2 Subject to the terms and conditions of this Agreement, the Company
hereby grants each Holder the right to deliver to the Company all or part of its Series A Preferred Shares at any time in a cashless exchange for delivery of Common Shares (the “Put Option”) in accordance with the Conversion Ratio
and pursuant to the Put Transfer Notice delivered by such Holder. 
 5.3 Each Holder shall, at all times, have the right to
issue a revocable notice to the Company that it intends to issue a Put Transfer Notice (the “Put Transfer Indication”). The Company shall use the period from (i) receipt of the Put Transfer Indication to (ii) receipt of
the Put Transfer Notice, to prepare any actions and steps that may be required to allow it to satisfy an exercise of the Put Option pursuant to a Put Transfer Notice in the timeframes set out in Clause 5.1. There shall be no limit on the number of
Put Transfer Indications that a Holder is permitted to issue per calendar year but no such notice shall be issued within 60 Business Days of a previous Put Transfer Indication unless approved by the Company (such approval not to be unreasonably
withheld or delayed). 
 6. Grant of Call Option 

6.1 Upon satisfaction of the conditions in Clause 6.2, the Company shall have the right to issue a notice to the Holders
specifying the date and time on which the Call Option (as defined below) is to be exercised (the “Call Transfer Notice”), which shall be a date at least twenty (20) days after the date on which such Call Transfer Notice is
delivered to the Holders, or such other date and time as the Holders of a majority of the Series A Preferred Shares from time to time (the “Preferred Holder Majority”) and the Company may agree (the “Call Effective
Time”). 
 6.2 Subject to the terms and conditions of this Agreement, the Holders hereby grant the Company the right
to require the Holders to deliver all or part of their Series A Preferred Shares (pro-rata among all Holders to their then holding of Series A Preferred Shares) in a cashless exchange for delivery of Common
Shares (the “Call Option”) in accordance with the Conversion Ratio and pursuant to the Call Transfer Notice delivered by the Company, provided that: 

(a) such Holder is not at the Call Effective Time restricted from making a Transfer (as defined in the Shareholders Agreement) pursuant to
Section 3.2 of the Shareholders Agreement; 
 (b) the Call Effective Time is not in a Blackout Period (as defined in the Registration
Rights Agreement); and 

 (c) the Value of the Common Shares at the date of the Call Transfer Notice equals or exceeds
$18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like). 
 7.
Redemption 
 7.1 Subject to this Agreement and mandatory Swiss law, including without limitation, Article 659
et seq. Swiss Code of Obligations, and provided that (i) no Put Option or Call Option has been exercised in accordance with a Put Transfer Notice or Call Transfer Notice (as applicable) in respect of the relevant Series A Preferred Shares,
(ii) there are sufficient capital contribution reserves of the Company so that the payment of the redemption consideration is not a distribution subject to Swiss Federal Withholding Tax (the “Capital Contribution
Reserves”) available to effect the redemption (as set out in Clause 7.2 below) (or alternatively, the Company has obtained a tax ruling from the Swiss Federal Tax Authority that the redemption is not a payment or distribution subject to
Swiss taxes including but not limited to Swiss Federal Withholding, in a form reasonably satisfactory to the Holders of a majority of Series A Preferred Shares, for other reasons including without limitation where Swiss Federal Withholding tax has
been abolished), and (iii) the Value of each Series A Preferred Shares on an As-Converted Basis is equal to or greater than $10.00, the Company shall have the right but not the obligation to issue a
preliminary notice to the Holders of its potential intention to redeem some or all of the Series A Preferred Shares (pro-rata among all Holders to their then holding of Series A Preferred Shares) following the
fifth anniversary of the Closing Date or, if earlier, upon a change of control of the Company which would result in the Holders of the Series A Preferred Shares receiving an amount equal to or greater than $10.00 per Series A Preferred Share (the
“Redemption Transfer Intention”). After thirty (30) calendar days following but within 45 days following the Redemption Transfer Intention, the Company shall have the right to issue an irrevocable notice of its intention to
redeem the Series A Preferred Shares which were the subject of the Redemption Transfer Intention (the “Redemption Transfer Notice”) provided the VWAP of the Series A Preferred Shares on an
As-Converted Basis on the trading day prior to the Redemption Transfer Notice is equal to or greater than $10.00. The Redemption Transfer Notice shall specify the date and time on which the Redemption (as
defined below) is to be completed, which shall be no later than two (2) Business Days following the date of the Redemption Transfer Notice (the “Redemption Effective Time”). There shall be no limit on the number of
Redemption Transfer Intentions that the Company is permitted to issue per calendar year but no such notice shall be issued within 60 Business Days of a previous Redemption Transfer Intention unless approved by the Preferred Holder Majority (such
approval not to be unreasonably withheld or delayed). 
 7.2 Following issue of a valid Redemption Transfer Notice in
accordance with Clause 7.1, the Company may redeem some or all of the Series A Preferred Shares (pro-rata among all Holders) (the “Redemption”) at the Redemption Effective Time for the VWAP of
the Series A Preferred Shares on an As-Converted Basis on the trading day prior to the Redemption Effective Time on an As-Converted Basis, payable in cash or Common
Shares (at the Company’s election) (such amount being the “Redemption Amount”). 

 7.3 If the conditions in Clause 7.1(i) are satisfied but Clause 7.1(ii) is
not satisfied because there are insufficient Capital Contribution Reserves to effect the Redemption (but all other mandatory Swiss law requirements, including Article 659 et seq. Swiss Code of Obligations, are complied with), the Company shall still
have the right to issue a Redemption Transfer Notice specifying the Redemption Effective Time, which shall in this case be a date at least forty (40) calendar days after the date on which such notice is delivered to the Holders or such other
date and time as the Preferred Holder Majority and the Company may agree. Such Redemption Transfer Notice shall also provide each Holder with the right to exercise the Put Option (in substitution for the Redemption, which would no longer occur),
provided that such Holder delivers a Put Transfer Notice in accordance with Clause 5.1 above and so long as the Put Transfer Notice is delivered to the Company on a date at least ten (10) calendar days prior to the Redemption Effective Time.

 8. Transfer Procedures. 

8.1 Issuance and Delivery of Common Shares. 

(a) If the Holder(s) and/or a Preferred Holder Majority (as applicable) validly deliver a Transfer Notice to the Company or the Company validly
delivers a Transfer Notice to the Holder(s), and the Holder(s) surrender to the Company on or before the Effective Time the Series A Preferred Shares subject to such Transfer Notice, the Company shall deliver or cause to be delivered immediately
following the Effective Time to the Holder(s) certificates (or book-entry shares) representing Common Shares in respect to the Series A Preferred Shares subject to such Transfer Notice. 

(a) From and after the Effective Time, the relevant Holders shall cease to be entitled to any rights or privileges attached to the Series A
Preferred Shares that are subject to the relevant Transfer Notice. The Company shall hold such Series A Preferred Shares in treasury, propose at the next ordinary general meeting of shareholders their cancellation and implement such resolution in
accordance with Swiss law. 
 8.2 Conditions. 

(a) The obligations of the relevant Holder to consummate the transactions at the Effective Time shall be subject to the satisfaction at the
Effective Time of the following condition, which may be waived, in writing, exclusively by the Preferred Holder Majority or such Holder (as applicable): the representations and warranties of the Company contained in this Agreement shall be true and
correct in all respects as of (i) the Closing Date, as if made on and as of the Closing Date, and (ii) the Effective Time, as if made on and as of the Effective Time. 

(b) The obligations of the Company to consummate the transactions at the Effective Time shall be subject to the satisfaction at the Effective
Time of the following conditions, which may be waived, in writing, exclusively by the Company: the representations and warranties of the relevant Holder contained in this Agreement shall be true and correct in all respects as of the Effective Time,
as if made on and as of the Effective Time. 

 9. Representations and Warranties of the Company. 

9.1 The Company represents and warrants to the Holder as of the Closing Date and the Effective Time as follows: 

(a) Organization and Qualification. The Company is duly organized and in good standing under the laws of Switzerland. 

(b) Power and Authority. As of the date hereof, the Company has the power and authority to enter into, execute, deliver and carry
out the terms of this Agreement provided for herein, all of which have been duly authorized by all proper and necessary action and are not prohibited by the organizational instruments of the Company. 

(c) Binding Obligation. This Agreement, when executed and delivered, will constitute the valid and legally binding obligation of
the Company, enforceable against the Company in accordance with its terms, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights
generally. 
 (d) No Conflict. The execution, delivery and performance by the Company of this Agreement does not and will not:
(i) violate any provision of law applicable to the Company, the organizational documents of the Company, or any order, judgment or decree of any court or other agency of government binding on the Company; (ii) conflict with, result in a
breach of or constitute (with due notice or lapse of time or both) a default under any contract or agreement to which the Company is a party or by which the Company or its respective property is bound; (iii) result in or require the creation or
imposition of any lien upon any of the properties or assets of the Company; or (iv) require any approval or consent of the Company under any contract or agreement to which the Company is a party or by which the Company or its respective
property is bound. 
 10. Representations and Warranties of the Holder. 

10.1 Each Holder represents and warrants to the Company as of the date hereof and as of the Effective Time as follows with
respect to itself only: 
 (a) Organization and Qualification. The Holder, where not a natural person, is duly organized and in
good standing under the laws of its place of establishment. 
 (b) Power and Authority. As of the date hereof, the Holder has the
power and authority to enter into, execute, deliver and carry out the terms of this Agreement provided for herein, all of which have been duly authorized by all proper and necessary action and, where the Holder is not a natural person, are
not prohibited by the organizational instruments of the Holder. 
 (c) Binding Obligation. This Agreement, when executed and
delivered, will constitute the valid and legally binding obligation of the Holder, enforceable against the holder in accordance with its terms, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting the enforcement of creditors’ rights generally. 
 (d) No Conflict. The execution, delivery
and performance by the Holder of this Agreement does not and will not: (i) violate any provision of law applicable to the Holder, any organizational documents of the Holder, or any order, judgment or decree of any court or other agency
of government binding on the Company; (ii) conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any contract or agreement to which the Holder is a party or by which the Holder or its
respective property is bound; (iii) result in or require the creation or imposition of any lien upon any of the properties or assets of the Holder; or (iv) require any approval or consent of the Holder under any contract or agreement to
which the Holder is a party or by which the Holder or its respective property is bound. 

 (e) No Encumbrance: the Holder has not (i) granted to any Person (other than
an Affiliate) any option, warrant or other rights to purchase or subscribe for any of such Series A Preferred Shares; or (ii) otherwise entered into any contract, commitment, agreement, understandings or arrangements providing for the sale
or transfer of any of such Series A Preferred Shares, excluding in each case any arrangement that may be disclosed in a pending Transfer Notice. Subject to any rights of any proposed transferee referenced in a pending Transfer Notice, each Holder
has good and marketable title to the Series A Preferred Shares, free and clear of any and all liens. 
 11. Anti-dilution 

11.1 If after the date hereof, and subject to the provisions of Clause 11.3 below, the number of outstanding Common Shares is increased by a split-up of Common Shares or other similar event, then, on the effective date of such split-up or similar event, the number of Common Shares issuable on the exchange of each
Series A Preferred Share shall be increased in proportion to such increase in the outstanding Common Shares. 
 11.2 If after the date
hereof, and subject to the provisions of Clause 11.3 hereof, the number of outstanding Common Shares is decreased by a consolidation, combination, reverse share split or reclassification of Common Shares or other similar event, then, on the
effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of Common Shares issuable on the exchange of each Series A Preferred Share shall be decreased in proportion to such decrease in
outstanding Common Shares. 
 11.3 If, by reason of any adjustment made pursuant to this Agreement, a Holder would be entitled, upon the
exercise of such Series A Preferred Share, to receive a fractional interest in a Common Share, the Company shall, upon such exchange, round to the nearest whole number for the number of Common Shares to be issued to such Holder. 

12. Class Consent 

If the Company intends to incur or increase Indebtedness and: (i) such Indebtedness would result in the Indebtedness Ratio being greater
than five (5); and (ii) at the time of the proposed increase of such Indebtedness there would be at least EUR €25,000,000 of Series A Preferred Shares (based on a value of $10.00 per Series A Preferred Share and the average of the spot
exchange rate as at 5:00 pm, New York time, on the five (5) Business Days ending five (5) Business Days before the Closing Date, as published by Bloomberg) outstanding, the proposed increase will require the prior written approval of the
Preferred Holder Majority prior to such increase. 

 13. Waiver of right to board representative. 

Each Holder acknowledges and agrees that the Articles do not provide for a board representative of holders of Series A Preferred Shares, and
hereby waives the right for such board representative solely as a result of its holding of Series A Preferred Shares. For the avoidance of doubt, nothing in this Agreement shall have the effect of limiting or waiving any right that a Holder may have
to nominate a board representative under any other agreement, arrangement or otherwise. 
 14. Registration and Voting
Limitations. 
 Each Holder acknowledges that the Common Shares to be delivered to any Holder under this Agreement will be subject to
Swiss law and the Articles as in effect from time to time including the generally applicable shareholder registration and voting limitations as may be set out in the Articles from time to time. 

15. Assignment. 

The Holders may transfer Series A Preferred Shares and assign their rights under this Agreement, subject only to the Articles and conditional
upon to such transferee or assignee executing a Joinder Agreement in the form attached as Schedule 2 on or prior to such transfer. 
 16.
Termination of Agreement. 
 This Agreement shall be terminated upon mutual written agreement of hereto or when no
Series A Preferred Shares are held by any Holder provided that nothing herein shall relieve any party hereto from any liability or damages resulting from any breach of its obligations under this Agreement prior to termination. Notwithstanding
anything contained herein to the contrary, Clauses 15 to 23 (inclusive) shall survive any termination of any provisions of this Agreement. 

17. No Waiver of Rights. 

No delay or failure on the part of the Company or any Holder, to exercise any right, power or privilege under this Agreement or any other
agreement shall operate as a waiver thereof, and no single or partial exercise of any right, power or privilege shall preclude any other or further exercise thereof or the exercise of any other power or right, or be deemed to establish a custom or
course of dealing or performance between the parties hereto. The rights and remedies herein provided are cumulative and not exclusive of any rights or remedies provided by law. No notice to or demand on the Company or any Holder in any case shall
entitle such Person to any other or further notice or demand in the same, similar or other circumstance. 
 18. Fees and
Expenses. 
 Any applicable Swiss Securities Transfer Tax (Umsatzabgabe) shall be paid and borne by the Company. 

 19. Modification. 

The terms of this Agreement may be waived, discharged or terminated only by an instrument in writing signed by the party (which, in the case of
any Manager, may be executed and 
 delivered by the Management Representative) against which enforcement of the change, waiver, discharge or termination is
sought. No amendment, modification, waiver or other change of any of the terms of this Agreement shall be effective without the prior written consent of the Company and the SL/PG Shareholders (and, if the amendment or modification would have a
material and disproportionate adverse effect on the Managers, then such instrument in writing shall be signed by the Management Representative as well). 

20. Severability. 

In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or
unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect only if, after excluding the portion deemed to be unenforceable, the remaining
terms shall provide for the consummation of the transactions contemplated hereby in substantially the same manner as originally set forth at the later of the date this Agreement was executed or last amended. 

21. Notices. 

All notices and other communications hereunder shall be in writing and shall be deemed given (a) when delivered personally, (b) when
sent by reputable overnight courier service or (c) when telecopied or emailed (which is confirmed by copy sent within one business day by a reputable overnight courier service) to the parties at the following addresses (or at such other address for
a party as shall be specified by like notice): 
 If to the Company: 

Jeremy Henderson-Ross 
 General
Counsel 
 Global Blue Group AG 

Route de Crassier 7 
 1262
Eysins 
 Switzerland 
 If to
the SL Shareholder: 
 c/o Maples Corporate Services Limited 

PO Box 309, Ugland House 
 Grand
Cayman, KY1-1104 
 Cayman Islands 

Attention: Legal Depart. 

Email: LegalStaff-UK@silverlake.com 

with copies (which shall not constitute notice) to: 

c/o Silver Lake Europe LLP 

Broadbent House, 65 Grosvenor Street, 

London W1K 3LH 
 Attention:
Legal Depart. 
 Email: LegalStaff-UK@silverlake.com 

 and 

Simpson Thacher & Bartlett LLP 

Citypoint, One Ropemaker Street 

London EC2Y 9HU 
 Attention:
Clare Gaskell 
 Email: cgaskell@stblaw.com 

If to the PG Shareholder: 
 c/o
Maples Corporate Services Limited 
 PO Box 309, Ugland House 

Grand Cayman, KY1-1104 

Cayman Islands 
 Email:
pgadmin@partnersgroup.com 
 If to any Manager: 

such notice shall be addressed or sent to the relevant 

Manager at the address set out in his/her Joinder 

Agreement, 
 or to such other address or to such
other Person as any party shall have last designated by such notice to the other parties. 
 22. Governing Law and
Jurisdiction 
 This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the transactions
contemplated hereby, shall be governed by, and construed in accordance with, the Laws of Delaware, without giving effect to principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of
Laws of another jurisdiction. 
 Any dispute, controversy or claim arising out of or relating to this Agreement, including any question regarding its
conclusion, existence, validity, invalidity, breach, amendment or termination (each, a “Dispute”), shall be finally resolved by arbitration under Rules of Arbitration of the International Chamber of Commerce (the “ICC”) in force
at the time of such submission (the “Rules”). The Rules are deemed to be incorporated by reference into this Agreement except: (i) that any provision of such Rules relating to the appointment of an emergency arbitrator shall be
excluded in its entirety; and (ii) as may be agreed by the Parties. 

 The number of arbitrators shall be three. The Claimant(s) shall nominate one arbitrator in the Request for
Arbitration. The Respondent(s) shall nominate one arbitrator in the Answer to the Request. The two party-nominated arbitrators will then attempt to agree for a period of 30 days, in consultation with the parties to the arbitration, upon the
nomination of a third arbitrator to act as president of the tribunal, barring which the International Court of Arbitration of the ICC shall select the third arbitrator (or any arbitrator that Claimant(s) or Respondent(s) shall fail to nominate in
accordance with the foregoing). 
 The seat of arbitration shall be Zurich, Switzerland. The language of the arbitration shall be English. 

The arbitral proceedings shall be subject to the provisions of Chapter 12 of the Swiss Private International Act, to the exclusion of the Third Part of the
Swiss Code of Civil Procedure. 
 The Parties shall maintain strict confidentiality with respect to all aspects of the arbitration and shall not disclose
the existence of the arbitration, the arbitral proceedings, the submissions or the decisions made by the arbitral tribunal, including its awards to any non-parties or
non-participants without the prior written consent of all parties to the arbitration, except to the extent: (i) required by law and applicable internal reporting requirements; or (ii) necessary to
recognize, confirm or enforce the final award in the arbitration. 
 The Parties hereby agree that, in the event of a dispute relating to any matter
contained both in this Agreement and in the Articles, the provisions of this Agreement will prevail and, in particular, the provisions of this Clause 22 shall take precedence over the dispute resolution provisions in the Articles. 

23. Remedies; Specific Performance. 

The parties to this Agreement agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not
performed by the Company in accordance with their specific terms or were otherwise breached. It is accordingly agreed that prior to the termination of this Agreement in accordance with Clause 16, the Company will be entitled to an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in any competent court of jurisdiction, this being in addition to any other remedy to which they are entitled at law or in
equity. 
 24. No Recourse. 

This Agreement may only be enforced against, and any claims or cause of action that may be based upon, arise out of or relate to this
Agreement, or the negotiation, execution or performance of this Agreement may only be made against the parties that are expressly identified as parties hereto and no other past, present or future Affiliate, director, officer, employee, incorporator,
member, manager, general or limited partner, shareholder, controlling person, fiduciary, agent, attorney or representative of any party hereto, or any other past, present or future Affiliate, director, officer, employee, incorporator, member,
manager, general or limited partner, shareholder, controlling person, fiduciary, agent, attorney or representative of any of the foregoing shall have any liability for any obligations or liabilities of the parties to this Agreement or for any claim
based on, in respect of, or by reason of, the transactions contemplated hereby. Each party (other than a Manager) shall be entitled to enforce this clause against any other party on behalf of a person referred to in this clause. 

 25. Accounting Treatment 

The parties hereby agree that, as of the date hereof, the intention is for the terms and conditions set out in this Agreement to enable the
instrument to be characterized as an equity instrument in the Company’s accounts. 
 [signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

			
	GLOBAL BLUE GROUP HOLDING AG
		
	By:	 	 /s/ Marcel Erni

	Name:	 	Marcel Erni
	Title:	 	Director

 [Signature Page GB Pref Conversion Agreement (2(i))] 

 
			
	GLOBAL BLUE HOLDING LP
	
	By its general partner:
	
	SL GLOBETROTTER GP, LTD
		
	By:	 	 /s/ Joseph Osnoss

	Name:	 	Joseph Osnoss
	Title:	 	Director

 [Signature Page GB Pref Conversion Agreement (2(i))] 

 
			
	SL GLOBETROTTER LP
	
	By its general partner:
	
	SL GLOBETROTTER GP, LTD
		
	By:	 	 /s/ Joseph Osnoss

	Name:	 	Joseph Osnoss
	Title:	 	Director

 [Signature Page GB Pref Conversion Agreement (2(i))] 

 Schedule 1 

FORM OF JOINDER AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement pursuant to that certain Conversion Agreement, dated as of_______________
2020 (as amended, restated, supplemented or otherwise modified in accordance with the terms thereof, the “Conversion Agreement”) by and between (i) Global Blue Group Holding AG, a Swiss corporation (the
“Company”), (ii) Global Blue Holding LP, an exempted limited partnership formed under the laws of the Cayman Islands, having its registered office at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand
Cayman, KY1-1104, Cayman Islands and registered in the Cayman Islands General Registry under number 95120 (the “PG Shareholder”), (iii) SL Globetrotter L.P., an exempted limited partnership
formed under the laws of the Cayman Islands, having its registered office at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and registered in
the Cayman Islands General Registry under number 95120 (the “SL Shareholder” and, together with the PG Shareholder, the “SL/PG Shareholders”) and (iv) the several persons whose names and addresses are set out
in each of his/her respective Joinder Agreements (each a “Manager” and, together, the “Managers”, and together with the SL/PG Shareholders, the “Holders”), and any other Persons who become a party
thereto in accordance with the terms thereof. Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the Conversion Agreement. 

By executing and delivering this Joinder Agreement to the Conversion Agreement, the undersigned hereby adopts and approves the Conversion
Agreement and agrees, effective commencing on the date hereof and as a condition to the undersigned’s becoming the beneficial owner and/or transferee of certain Series A Preferred Shares, to become a party as a “Holder” and to be
bound by and comply with the provisions of, the Conversion Agreement applicable to the such assigning Holder, in the same manner as if the undersigned were an original signatory to the Conversion Agreement. 

The undersigned acknowledges and agrees that Clauses 15 to 23 of the Conversion Agreement is incorporated herein by reference, mutatis
mutandis. 
 Accordingly, Jacques Stern as duly appointed attorney of [MANAGER] has executed and delivered this Joinder Agreement as of
__________________ 2020 
  

			
	  

(Signature)

		
	Address:	 	
                     
       

		 	  

		 	  

		
	Email address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]